Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on February 26.
David Risinger has given his Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ potential in the outpatient market. The company’s recently approved NaV1.8 inhibitor, Journavx, is expected to gain significant traction in the outpatient setting, despite concerns about its limited use in inpatient settings where opioids are preferred for pain management. Risinger believes that the outpatient market presents a substantial opportunity for Journavx, particularly as patients transition from hospital care to home care.
Vertex’s strategic initiatives, such as offering initial free or low-cost prescriptions and financial assistance programs, are designed to enhance patient access and drive early adoption of Journavx. The company’s efforts to secure broad drug benefit access without restrictive prior authorizations are expected to support strong sales growth. Risinger projects that Journavx will achieve sales significantly above consensus estimates, with a promising outlook for both acute and neuropathic pain markets. This optimistic sales projection underpins the Buy rating, reflecting confidence in Vertex’s ability to capitalize on the outpatient market potential.
According to TipRanks, Risinger is a 5-star analyst with an average return of 10.3% and a 56.15% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, AnaptysBio, and Regeneron.